{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:56:42Z","timestamp":1790697402126,"version":"4.1.0"},"reference-count":106,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Hospitals Authority Clinical Medicine Development Special Funding Support","award":["ZLRK202518"],"award-info":[{"award-number":["ZLRK202518"]}]},{"name":"Beijing Natural Science Foundation","award":["L242046"],"award-info":[{"award-number":["L242046"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Congenital long QT syndrome (LQTS), the first identified cardiac ion channelopathy, is characterized by delayed ventricular repolarization and a prolonged heart rate-corrected QT interval (QTc), conferring an increased risk of malignant ventricular arrhythmias and sudden cardiac death. Current standard-of-care management for LQTS, including beta-blockers, sodium channel blockers, left cardiac sympathetic denervation (LCSD), and implantable cardioverter-defibrillators (ICDs), reduces adverse events and improves survival but primarily mitigates downstream electrophysiological consequences rather than correcting the underlying genetic defects. Rapid advances in molecular biology have driven the development of mechanism-directed strategies such as gene editing, RNA interference (RNAi), and experimental antibody-based interventions, which aim to restore channel function or modulate channel regulation at the source. This review synthesizes current knowledge on LQTS classification and pathogenesis and evaluates both guideline-directed therapies and emerging molecular interventions. We emphasize subtype-specific approaches, highlight the rationale and preclinical progress for gene- and RNA-based therapies, and outline practical considerations for translation, including delivery, durability, and safety. Therefore, this review provides a comprehensive, mechanism-based framework to inform future precision medicine approaches for LQTS.<\/jats:p>","DOI":"10.31083\/rcm51843","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:11Z","timestamp":1790693831000},"source":"Crossref","is-referenced-by-count":0,"title":["Congenital Long QT Syndrome: From Conventional Management to Emerging Biological Therapies"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-2857","authenticated-orcid":true,"given":"Qing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of General Practice, Suining Central Hospital, 629000 Suining, Sichuan, China"},{"name":"Clinical Medical College, Qinghai University, 810000 Xining, Qinghai, China"},{"name":"Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-0974","authenticated-orcid":true,"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-1108","authenticated-orcid":true,"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-124X","authenticated-orcid":true,"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 102218 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Boczek NJ, Gomez-Hurtado N, Ye D, Calvert ML, Tester DJ, Kryshtal D, et al. Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G. Circulation. Cardiovascular Genetics. 2016; 9: 136\u2013146.","DOI":"10.1161\/CIRCGENETICS.115.001323"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Immanuel SA, Sadrieh A, Baumert M, Couderc JP, Zareba W, Hill AP, et al. T-wave morphology can distinguish healthy controls from LQTS patients. Physiological Measurement. 2016; 37: 1456\u20131473.","DOI":"10.1088\/0967-3334\/37\/9\/1456"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"C\u00f3cera-Ortega L, Wilders R, Kamps SC, Fabrizi B, Huber I, van der Made I, et al. shRNAs Targeting a Common KCNQ1 Variant Could Alleviate Long-QT1 Disease Severity by Inhibiting a Mutant Allele. International Journal of Molecular Sciences. 2022; 23: 4053.","DOI":"10.3390\/ijms23074053"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009; 120: 1761\u20131767.","DOI":"10.1161\/CIRCULATIONAHA.109.863209"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gibbs C, Thalamus J, Tveten K, Busk \u00d8L, Hysing J, Haugaa KH, et al. Genetic and Phenotypic Characterization of Community Hospital Patients With QT Prolongation. Journal of the American Heart Association. 2018; 7: e009706.","DOI":"10.1161\/JAHA.118.009706"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000; 101: 616\u2013623.","DOI":"10.1161\/01.cir.101.6.616"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Dusi V, Pugliese L, De Ferrari GM, Odero A, Crotti L, Dagradi F, et al. Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management. JACC. Clinical Electrophysiology. 2022; 8: 281\u2013294.","DOI":"10.1016\/j.jacep.2021.09.002"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Cavalcanti R, Aboul-Hosn N, Morales G, Abdel-Latif A. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy. Angiology. 2018; 69: 297\u2013302.","DOI":"10.1177\/0003319717710851"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Martinez K, Bains S, Giudicessi JR, Bos JM, Neves R, Ackerman MJ. Spectrum and prevalence of side effects and complications with guideline-directed therapies for congenital long QT syndrome. Heart Rhythm. 2022; 19: 1666\u20131672.","DOI":"10.1016\/j.hrthm.2022.06.008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"O'Hare BJ, John Kim CS, Hamrick SK, Ye D, Tester DJ, Ackerman MJ. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes. Circulation. Genomic and Precision Medicine. 2020; 13: 466\u2013475.","DOI":"10.1161\/CIRCGEN.120.002950"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Friedmann T, Roblin R. Gene therapy for human genetic disease? Science (New York, N.Y.). 1972; 175: 949\u2013955.","DOI":"10.1126\/science.175.4025.949"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Lalaguna L, Ramos-Hern\u00e1ndez L, Priori SG, Lara-Pezzi E. Genome Editing and Inherited Cardiac Arrhythmias. Advances in Experimental Medicine and Biology. 2023; 1396: 115\u2013127.","DOI":"10.1007\/978-981-19-5642-3_8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Li G, Ma S, Sun C. RNA interference-based therapeutics for inherited long QT syndrome. Experimental and Therapeutic Medicine. 2015; 10: 395\u2013400.","DOI":"10.3892\/etm.2015.2573"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Kim M, Das S, Tester DJ, Pradhananga S, Hamrick SK, Gao X, et al. SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome. Heart Rhythm O2. 2023; 4: 268\u2013274.","DOI":"10.1016\/j.hroo.2023.02.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Clemens DJ, Tester DJ, Giudicessi JR, Bos JM, Rohatgi RK, Abrams DJ, et al. International Triadin Knockout Syndrome Registry. Circulation. Genomic and Precision Medicine. 2019; 12: e002419.","DOI":"10.1161\/CIRCGEN.118.002419"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation. 2020; 141: 418\u2013428.","DOI":"10.1161\/CIRCULATIONAHA.119.043132"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Mandal B, Kaur G, Batra YK, Mahajan S. Manifestation of Long QT syndrome with normal QTc interval under anesthesia: a case report. Paediatric Anaesthesia. 2011; 21: 1265\u20131267.","DOI":"10.1111\/j.1460-9592.2011.03679.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. European Heart Journal. 2016; 37: 1456\u20131464.","DOI":"10.1093\/eurheartj\/ehv695"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lim GB. Reappraisal of LQTS-causing genes. Nature Reviews. Cardiology. 2020; 17: 200\u2013201.","DOI":"10.1038\/s41569-020-0349-0"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Morgat C, Fressart V, Porretta AP, Neyroud N, Messali A, Temmar Y, et al. Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2024; 26: euae136.","DOI":"10.1093\/europace\/euae136"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ritt LE, Milani M, Stein R. Long QT syndrome: to exercise safely or not to exercise, that's the question!!! European Journal of Preventive Cardiology. 2022; 29: 1630\u20131632.","DOI":"10.1093\/eurjpc\/zwac109"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Itoh H, Berthet M, Fressart V, Denjoy I, Maugenre S, Klug D, et al. Asymmetry of parental origin in long QT syndrome: preferential maternal transmission of KCNQ1 variants linked to channel dysfunction. European Journal of Human Genetics: EJHG. 2016; 24: 1160\u20131166.","DOI":"10.1038\/ejhg.2015.257"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001; 103: 89\u201395.","DOI":"10.1161\/01.cir.103.1.89"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kutyifa V, Daimee UA, McNitt S, Polonsky B, Lowenstein C, Cutter K, et al. Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3). Annals of Noninvasive Electrocardiology: the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2018; 23: e12537.","DOI":"10.1111\/anec.12537"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wu ZJ, Huang Y, Fu YC, Zhao XJ, Zhu C, Zhang Y, et al. Characterization of a Chinese KCNQ1 mutation (R259H) that shortens repolarization and causes short QT syndrome 2. Journal of Geriatric Cardiology: JGC. 2015; 12: 394\u2013401.","DOI":"10.11909\/j.issn.1671-5411.2015.04.002"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009; 6: 1297\u20131303.","DOI":"10.1016\/j.hrthm.2009.05.021"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ge N, Liu M, Krawczyk J, McInerney V, Ward D, Shen S, et al. Generation and characterization of an induced pluripotent stem cell (iPSC) line (NUIGi003-A) from a long QT syndrome type 2 (LQT2) patient harbouring the KCNH2 c.2464G>A pathogenic variant. Stem Cell Research. 2020; 49: 101997.","DOI":"10.1016\/j.scr.2020.101997"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Mond\u00e9jar-Parre\u00f1o G, Jahng JWS, Belbachir N, Wu BC, Zhang X, Perez MV, et al. Generation of three heterozygous KCNH2 mutation-carrying human induced pluripotent stem cell lines for modeling LQT2 syndrome. Stem Cell Research. 2021; 54: 102402.","DOI":"10.1016\/j.scr.2021.102402"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ficker E, Dennis AT, Obejero-Paz CA, Castaldo P, Taglialatela M, Brown AM. Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome. Journal of Molecular and Cellular Cardiology. 2000; 32: 2327\u20132337.","DOI":"10.1006\/jmcc.2000.1263"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhao Y, Ma S, Cao M, Sun C. G604S-HERG mutation in LQT2 leads to autophagy via the UPR-related pathway. Journal of Biosciences. 2020; 45: 90.","DOI":"10.1007\/s12038-020-00066-x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Marstrand P, Almatlouh K, Kanters JK, Graff C, Christensen AH, Bundgaard H, et al. Long QT syndrome type 1 and 2 patients respond differently to arrhythmic triggers: The TriQarr invivo study. Heart Rhythm. 2021; 18: 241\u2013249.","DOI":"10.1016\/j.hrthm.2020.08.017"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"DeMaria N, Selmi A, Kashtan S, Xia X, Wang M, Zareba W, et al. Autonomic and Cardiac Repolarization Lability in Long QT Syndrome Patients. Autonomic Neuroscience: Basic & Clinical. 2020; 229: 102723.","DOI":"10.1016\/j.autneu.2020.102723"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Brand\u00e3o KO, van den Brink L, Miller DC, Grandela C, van Meer BJ, Mol MPH, et al. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias. Stem Cell Reports. 2020; 15: 1127\u20131139.","DOI":"10.1016\/j.stemcr.2020.10.005"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Ge N, Li R, Liu M, Xia W, O'Brien ST, McInerney V, et al. Defining Cardiomyocyte Repolarization Response to Pharmacotherapy in Long-QT Syndrome Type 3. Journal of the American Heart Association. 2024; 13: e034690.","DOI":"10.1161\/JAHA.124.034690"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Wu X, Hoeker GS, Blair GA, King DR, Gourdie RG, Weinberg SH, et al. Hypernatremia and intercalated disc edema synergistically exacerbate long-QT syndrome type 3 phenotype. American Journal of Physiology. Heart and Circulatory Physiology. 2021; 321: H1042\u2013H1055.","DOI":"10.1152\/ajpheart.00366.2021"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Chen J, Li H, Guo S, Yang Z, Sun S, Zeng J, et al. Whole exome sequencing in Brugada and long QT syndromes revealed novel rare and potential pathogenic mutations related to the dysfunction of the cardiac sodium channel. Orphanet Journal of Rare Diseases. 2022; 17: 394.","DOI":"10.1186\/s13023-022-02542-z"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P, et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovascular Research. 2011; 92: 67\u201374.","DOI":"10.1093\/cvr\/cvr166"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology. 2003; 42: 103\u2013109.","DOI":"10.1016\/s0735-1097(03)00554-0"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Bauer R, Timothy KW, Golden A. Update on the Molecular Genetics of Timothy Syndrome. Frontiers in Pediatrics. 2021; 9: 668546.","DOI":"10.3389\/fped.2021.668546"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Chen X, Birey F, Li MY, Revah O, Levy R, Thete MV, et al. Antisense oligonucleotide therapeutic approach for Timothy syndrome. Nature. 2024; 628: 818\u2013825.","DOI":"10.1038\/s41586-024-07310-6"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Tang ZZ, Sharma S, Zheng S, Chawla G, Nikolic J, Black DL. Regulation of the mutually exclusive exons 8a and 8 in the CaV1.2 calcium channel transcript by polypyrimidine tract-binding protein. The Journal of Biological Chemistry. 2011; 286: 10007\u201310016.","DOI":"10.1074\/jbc.M110.208116"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Birey F, Andersen J, Makinson CD, Islam S, Wei W, Huber N, et al. Assembly of functionally integrated human forebrain spheroids. Nature. 2017; 545: 54\u201359.","DOI":"10.1038\/nature22330"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Birey F, Li MY, Gordon A, Thete MV, Valencia AM, Revah O, et al. Dissecting the molecular basis of human interneuron migration in forebrain assembloids from Timothy syndrome. Cell Stem Cell. 2022; 29: 248\u2013264.e7.","DOI":"10.1016\/j.stem.2021.11.011"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Rodan LH, Spillmann RC, Kurata HT, Lamothe SM, Maghera J, Jamra RA, et al. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations. Genetics in Medicine: Official Journal of the American College of Medical Genetics. 2021; 23: 1922\u20131932.","DOI":"10.1038\/s41436-021-01232-8"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Conte G, Bergonti M, Probst V, Morita H, Tfelt-Hansen J, Behr ER, et al. aTrial arrhythmias in inhEriTed aRrhythmIa Syndromes: results from the TETRIS study. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2024; 26: euae288.","DOI":"10.1093\/europace\/euae288"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Extramiana F, Maison-Blanche P, Denjoy I, De Jode P, Messali A, Labb\u00e9 JP, et al. Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome. Annals of Noninvasive Electrocardiology: the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. 2013; 18: 399\u2013408.","DOI":"10.1111\/anec.12048"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Chorin E, Hu D, Antzelevitch C, Hochstadt A, Belardinelli L, Zeltser D, et al. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circulation. Arrhythmia and Electrophysiology. 2016; 9: e004370.","DOI":"10.1161\/CIRCEP.116.004370"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Sundstr\u00f6m E, Jensen SM, Diamant UB, Wiklund U, Rydberg A. ICD harm and benefit: risk scores applied to the Swedish ICD-treated LQTS population. Scandinavian Cardiovascular Journal: SCJ. 2022; 56: 48\u201355.","DOI":"10.1080\/14017431.2022.2060524"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Ahn J, Kim HJ, Choi JI, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PloS One. 2017; 12: e0185680.","DOI":"10.1371\/journal.pone.0185680"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004; 109: 1826\u20131833.","DOI":"10.1161\/01.CIR.0000125523.14403.1E"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Wang M, Peterson DR, Rosero S, McNitt S, Rich DQ, Seplaki CL, et al. Effectiveness of Implantable Cardioverter-Defibrillators to ReduceMortality in Patients With LongQT Syndrome. Journal of the American College of Cardiology. 2021; 78: 2076\u20132088.","DOI":"10.1016\/j.jacc.2021.09.017"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Li Q, Wang YF, Wang B, Lv TT, Zhang P. Induced Pluripotent Stem Cells in Congenital Long QT Syndrome: Research Progress and Clinical Applications. Reviews in Cardiovascular Medicine. 2025; 26: 28251.","DOI":"10.31083\/RCM28251"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Doherty I, Shetty R, Ni H, Morotti S, Grandi E. Exploring the mechanisms of sex-specific proarrhythmia in long QT syndrome through computational modeling. American Journal of Physiology. Heart and Circulatory Physiology. 2025; 328: H963\u2013H972.","DOI":"10.1152\/ajpheart.00792.2024"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Yang Y, Lv TT, Li SY, Zhang P. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis. Journal of Cardiovascular Electrophysiology. 2021; 32: 3057\u20133067.","DOI":"10.1111\/jce.15223"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Shimizu T, Kawai S, Kawada A, Wakamiya T, Nakano Y, Watanabe S, et al. Combined mexiletine and flecainide for severe long QT syndrome type 3. Pediatrics International: Official Journal of the Japan Pediatric Society. 2023; 65: e15517.","DOI":"10.1111\/ped.15517"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cant\u00f9 F, Towbin JA, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995; 92: 3381\u20133386.","DOI":"10.1161\/01.cir.92.12.3381"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Bos JM, Crotti L, Rohatgi RK, Castelletti S, Dagradi F, Schwartz PJ, et al. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. Circulation. Arrhythmia and Electrophysiology. 2019; 12: e007280.","DOI":"10.1161\/CIRCEP.118.007280"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Crotti L, Neves R, Dagradi F, Musu G, Giannetti F, Bos JM, et al. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients. Circulation. 2024; 150: 531\u2013543.","DOI":"10.1161\/CIRCULATIONAHA.124.068959"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Xu B, Li K, Liu F, Kong L, Yang J, Zhou B, et al. Mexiletine Shortened QT Interval and Reduced Ventricular Arrhythmias in a Pedigree of Type 2 Long QT Syndrome Combined with Left Ventricular Non-Compaction. International Heart Journal. 2021; 62: 427\u2013431.","DOI":"10.1536\/ihj.20-518"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Jang SY, Cho Y, Kim NK, Kim CY, Sohn J, Roh JH, et al. Video-Assisted Thoracoscopic Left Cardiac Sympathetic Denervation in Patients with Hereditary Ventricular Arrhythmias. Pacing and Clinical Electrophysiology: PACE. 2017; 40: 232\u2013241.","DOI":"10.1111\/pace.13008"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Niaz T, Bos JM, Sorensen KB, Moir C, Ackerman MJ. Left Cardiac Sympathetic Denervation Monotherapy in Patients With Congenital Long QT Syndrome. Circulation. Arrhythmia and Electrophysiology. 2020; 13: e008830.","DOI":"10.1161\/CIRCEP.120.008830"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed.). 2016; 69: 176.","DOI":"10.1016\/j.rec.2016.01.001"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"DiMarco JP. Implantable cardioverter-defibrillators. The New England Journal of Medicine. 2003; 349: 1836\u20131847.","DOI":"10.1056\/NEJMra035432"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Sun J, Zheng Y, Hu J. Targeting Microglia with Adeno-associated Viruses. Neuroscience Bulletin. 2023; 39: 863\u2013865.","DOI":"10.1007\/s12264-022-00975-x"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Greber UF. Adenoviruses - Infection, pathogenesis and therapy. FEBS Letters. 2020; 594: 1818\u20131827.","DOI":"10.1002\/1873-3468.13849"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Gill KP, Denham M. Optimized Transgene Delivery Using Third-Generation Lentiviruses. Current Protocols in Molecular Biology. 2020; 133: e125.","DOI":"10.1002\/cpmb.125"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Science Advances. 2023; 9: eade1444.","DOI":"10.1126\/sciadv.ade1444"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Yu Z, Goodall ECA, Henderson IR, Guo J. Plasmids Can Shift Bacterial Morphological Response against Antibiotic Stress. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2023; 10: e2203260.","DOI":"10.1002\/advs.202203260"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Fus-Kujawa A, Siero\u0144 \u0141, Dobrzy\u0144ska E, Chajec \u0141, Mendrek B, Jarosz N, et al. Star Polymers as Non-Viral Carriers for Apoptosis Induction. Biomolecules. 2022; 12: 608.","DOI":"10.3390\/biom12050608"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Craciun BF, Clima L, Bostiog DI, Silion M, Calin M, Peptanariu D, et al. Multilayer gold nanoparticles as non-viral vectors for targeting MCF-7 cancer cells. Biomaterials Advances. 2023; 144: 213201.","DOI":"10.1016\/j.bioadv.2022.213201"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Shi X, Bortolussi G, Collaud F, Le Brun PR, Bloemendaal LT, Guerchet N, et al. Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I. Molecular Therapy. Methods & Clinical Development. 2024; 32: 101363.","DOI":"10.1016\/j.omtm.2024.101363"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Bains S, Giammarino L, Nimani S, Alerni N, Tester DJ, Kim CSJ, et al. KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome. European Heart Journal. 2024; 45: 3751\u20133763.","DOI":"10.1093\/eurheartj\/ehae476"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Athukorala A, Helbig KJ, Mcsharry BP, Forwood JK, Sarker S. Adenoviruses in Avian Hosts: Recent Discoveries Shed New Light on Adenovirus Diversity and Evolution. Viruses. 2022; 14: 1767.","DOI":"10.3390\/v14081767"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Benskey MJ, Manfredsson FP. Lentivirus Production and Purification. Methods in Molecular Biology (Clifton, N.J.). 2016; 1382: 107\u2013114.","DOI":"10.1007\/978-1-4939-3271-9_8"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Lam K, Schreiner P, Leung A, Stainton P, Reid S, Yaworski E, et al. Optimizing Lipid Nanoparticles for Delivery in Primates. Advanced Materials (Deerfield Beach, Fla.). 2023; 35: e2211420.","DOI":"10.1002\/adma.202211420"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Wang T, You L. The persistence potential of transferable plasmids. Nature Communications. 2020; 11: 5589.","DOI":"10.1038\/s41467-020-19368-7"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Zhang F, Wen Y, Guo X. CRISPR\/Cas9 for genome editing: progress, implications and challenges. Human Molecular Genetics. 2014; 23: R40\u2013R46.","DOI":"10.1093\/hmg\/ddu125"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533: 420\u2013424.","DOI":"10.1038\/nature17946"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Publisher Correction: Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature. 2018; 559: E8.  Erratum for: Nature. 2017; 551: 464\u2013471. https:\/\/doi.org\/10.1038\/nature24644","DOI":"10.1038\/s41586-018-0070-x"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019; 576: 149\u2013157.","DOI":"10.1038\/s41586-019-1711-4"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Alayoubi AM, Khawaji ZY, Mohammed MA, Mercier FE. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia. Annals of Hematology. 2024; 103: 1805\u20131817.","DOI":"10.1007\/s00277-023-05457-2"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Qi M, Ma S, Liu J, Liu X, Wei J, Lu WJ, et al. In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice. Circulation. 2024; 149: 317\u2013329.","DOI":"10.1161\/CIRCULATIONAHA.123.065624"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al. Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. elife. 2022; 11: e81856.","DOI":"10.7554\/eLife.81856"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA Designs Further Improve InVivo Performance of GalNAc-siRNA Conjugates. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2018; 26: 708\u2013717.","DOI":"10.1016\/j.ymthe.2017.12.021"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Papadopoulos D, Ade CP, Eilers M. Generation of a pooled shRNA library for functional genomics screens. STAR Protocols. 2022; 3: 101183.","DOI":"10.1016\/j.xpro.2022.101183"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Stebbins CC, Petrillo M, Stevenson LF. Immunogenicity for antisense oligonucleotides: a risk-based assessment. Bioanalysis. 2019; 11: 1913\u20131916.","DOI":"10.4155\/bio-2019-0133"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Dainis A, Zaleta-Rivera K, Ribeiro A, Chang ACH, Shang C, Lan F, et al. Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics. 2020; 52: 293\u2013303.","DOI":"10.1152\/physiolgenomics.00021.2020"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Zaleta-Rivera K, Dainis A, Ribeiro AJS, Cordero P, Rubio G, Shang C, et al. Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation. 2019; 140: 765\u2013778.","DOI":"10.1161\/CIRCULATIONAHA.118.036965"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Goulet DR, Zwolak A, Williams JA, Chiu ML, Atkins WM. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Proteins. 2020; 88: 689\u2013697.","DOI":"10.1002\/prot.25853"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. The New England Journal of Medicine. 1985; 313: 337\u2013342.","DOI":"10.1056\/NEJM198508083130601"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Srinivasan L, Alzogaray V, Selvakumar D, Nathan S, Yoder JB, Wright KM, et al. Development of high-affinity nanobodies specific for NaV1.4 and NaV1.5 voltage-gated sodium channel isoforms. The Journal of Biological Chemistry. 2022; 298: 101763.","DOI":"10.1016\/j.jbc.2022.101763"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Ukachukwu CU, Jimenez-Vazquez EN, Salwi S, Goodrich M, Sanchez-Conde FG, Orland KM, et al. A PAS-targeting hERG1 activator reduces arrhythmic events in Jervell and Lange-Nielsen syndrome patient-derived hiPSC-CMs. JCI Insight. 2025; 10: e183444.","DOI":"10.1172\/jci.insight.183444"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Li J, Maguy A, Duverger JE, Vigneault P, Comtois P, Shi Y, et al. Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. Heart Rhythm. 2014; 11: 2092\u20132100.","DOI":"10.1016\/j.hrthm.2014.07.040"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Duan H, Zhang C, Zhang Z, Wang X, Zhang J, Yang L, et al. Gene therapy with covalently closed-end AAV vector for spinal muscular atrophy. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2025; 33: 4848\u20134857.","DOI":"10.1016\/j.ymthe.2025.06.028"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Horie T, Ono K. VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients. European Heart Journal. Cardiovascular Pharmacotherapy. 2024; 10: 89\u201390.","DOI":"10.1093\/ehjcvp\/pvad103"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Research. 2024; 120: 1400\u20131410.","DOI":"10.1093\/cvr\/cvae109"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A, et al. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry. Neurology(R) Neuroimmunology & Neuroinflammation. 2021; 8: e1088.","DOI":"10.1212\/NXI.0000000000001088"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Brunner M, Kodirov SA, Mitchell GF, Buckett PD, Shibata K, Folco EJ, et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. American Journal of Physiology. Heart and Circulatory Physiology. 2003; 285: H194\u2013203.","DOI":"10.1152\/ajpheart.00971.2002"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Giannetti F, Barbieri M, Shiti A, Casini S, Sager PT, Das S, et al. Gene- and variant-specific efficacy of serum\/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2023; 25: euad094.","DOI":"10.1093\/europace\/euad094"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Bezzerides VJ, Zhang A, Xiao L, Simonson B, Khedkar SA, Baba S, et al. Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders. Scientific Reports. 2017; 7: 346.","DOI":"10.1038\/s41598-017-00413-3"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Limpitikul WB, Dick IE, Tester DJ, Boczek NJ, Limphong P, Yang W, et al. A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome. Circulation Research. 2017; 120: 39\u201348.","DOI":"10.1161\/CIRCRESAHA.116.309283"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Li J, Seyler C, Wiedmann F, Schmidt C, Schweizer PA, Becker R, et al. Anti-KCNQ1 K\u207a channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy. Cardiovascular Research. 2013; 98: 496\u2013503.","DOI":"10.1093\/cvr\/cvt046"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Kis L, Li J. Proof of concept for monoclonal antibody therapy in a cellular model of acquired long QT syndrome type 3. American Journal of Physiology. Heart and Circulatory Physiology. 2024; 326: H89\u2013H95.","DOI":"10.1152\/ajpheart.00628.2023"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Maguy A, Kucera JP, Wepfer JP, Forest V, Charpentier F, Li J. KCNQ1 Antibodies for Immunotherapy of Long QT Syndrome Type 2. Journal of the American College of Cardiology. 2020; 75: 2140\u20132152.","DOI":"10.1016\/j.jacc.2020.02.067"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Yamamoto Y, Makiyama T, Harita T, Sasaki K, Wuriyanghai Y, Hayano M, et al. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation. Human Molecular Genetics. 2017; 26: 1670\u20131677.","DOI":"10.1093\/hmg\/ddx073"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Pan Z, Fu Q, Jiang H, Wei Z, Zhang S. Computational analysis of long QT syndrome type 2 and the therapeutic effects of KCNQ1 antibodies. Digital Health. 2024; 10: 20552076241277032.","DOI":"10.1177\/20552076241277032"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM51843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:34Z","timestamp":1790693914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM51843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03843-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm51843","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"51843"}}